v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information
Note 15 — Segment Information
Abbott’s principal business is the discovery, development, manufacture, and sale of a broad portfolio of healthcare products. Abbott’s products are generally sold directly to retailers, wholesalers, consumers, hospitals, healthcare facilities, laboratories, health systems, and government agencies throughout the world. On March 23, 2026, Abbott completed its acquisition of Exact Sciences. From the acquisition date, Abbott's results include Exact Sciences' results, which are reported within the Diagnostic Products segment as Cancer Diagnostics.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical and biologic products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems, tests, and automated solutions. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid and Molecular Diagnostics, and Cancer Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment reporting purposes, the Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer. The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.
Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General, and AdministrativeOperating Earnings
Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,
(in millions)2026202520262025202620252026202520262025
Established Pharmaceuticals$1,499 $1,383 $(650)$(631)$(48)$(43)$(419)$(363)$382 $346 
Nutritional Products2,144 2,212 (1,148)(1,155)(54)(54)(574)(585)368 418 
Diagnostic Products3,092 2,173 (1,532)(1,224)(268)(154)(793)(423)499 372 
Medical Devices 5,853 5,369 (1,925)(1,758)(470)(430)(1,489)(1,385)1,969 1,796 
Total$12,588 $11,137 $(5,255)$(4,768)$(840)$(681)$(3,275)$(2,756)$3,218 $2,932 
Other5 5 
Net sales$12,593 $11,142 
Corporate functions and plan benefit costs(45)(65)
Net interest expense(299)(50)
Share-based compensation (a)(168)(142)
Amortization of intangible assets(658)(420)
Other, net (b)(524)(105)
Earnings before Taxes$1,524 $2,150 
Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General, and AdministrativeOperating Earnings
Six Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,
(in millions)2026202520262025202620252026202520262025
Established Pharmaceuticals$2,925 $2,643 $(1,294)$(1,200)$(89)$(85)$(795)$(714)$747 $644 
Nutritional Products4,161 4,358 (2,237)(2,279)(108)(106)(1,137)(1,161)679 812 
Diagnostic Products5,272 4,227 (2,774)(2,376)(423)(305)(1,241)(815)834 731 
Medical Devices 11,392 10,264 (3,739)(3,356)(914)(831)(2,877)(2,672)3,862 3,405 
Total$23,750 $21,492 $(10,044)$(9,211)$(1,534)$(1,327)$(6,050)$(5,362)$6,122 $5,592 
Other7 8 
Net sales$23,757 $21,500 
Corporate functions and plan benefit costs(110)(93)
Net interest expense(367)(99)
Share-based compensation (a)(806)(431)
Amortization of intangible assets(1,080)(840)
Other, net (b)(786)(201)
Earnings before Taxes$2,973 $3,928 
___________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. The first six months of 2026 included $321 million of stock compensation expense related to the cash settlement of equity awards in connection with the Exact Sciences acquisition, per the terms of the merger agreement.
(b)
Other, net for the three and six months ended June 30, 2026, includes costs related to the acquisition of Exact Sciences, legal reserves, and restructuring charges. Other, net for the three and six months ended June 30, 2025, includes charges related to restructurings, fair value adjustments to contingent consideration and integration costs related to business combinations. Other, net for the six months ended June 30, 2025, also includes impairment charges related to various investments.
DepreciationAdditions to Property and Equipment
Three Months Ended June 30,Three Months Ended June 30,
(in millions)2026202520262025
Established Pharmaceuticals$25 $25 $36 $39 
Nutritional Products51 44 46 81 
Diagnostic Products165 135 157 166 
Medical Devices106 94 185 145 
Total Reportable Segments347 298 424 431 
Other55 59 75 62 
Total$402 $357 $499 $493 

DepreciationAdditions to Property and Equipment
Six Months Ended June 30,Six Months Ended June 30,
(in millions)2026202520262025
Established Pharmaceuticals$55 $48 $56 $72 
Nutritional Products101 86 86 160 
Diagnostic Products309 261 285 301 
Medical Devices206 182 332 301 
Total Reportable Segments671 577 759 834 
Other112 116 131 122 
Total$783 $693 $890 $956 
Total Assets
(in millions)As of June 30, 2026As of December 31, 2025
Established Pharmaceuticals$3,819 $3,540 
Nutritional Products5,278 4,791 
Diagnostic Products9,709 8,273 
Medical Devices11,406 10,689 
Total Reportable Segment Assets$30,212 $27,293 
Cash and investments6,714 9,857 
Goodwill and intangible assets52,455 29,561 
All other (c)19,834 20,002 
Total Assets$109,215 $86,713 
(c)As of June 30, 2026, and December 31, 2025, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.